AAFP Still Recommends CRC Screening From Age 50 to 75

Share this content:
AAFP Still Recommends CRC Screening From Age 50 to 75
AAFP Still Recommends CRC Screening From Age 50 to 75

WEDNESDAY, June 20, 2018 (HealthDay News) -- In accordance with the U.S. Preventive Services Task Force (USPSTF), the American Academy of Family Physicians (AAFP) does not intend to change its recommendations for colorectal cancer screening based on the recent change in the American Cancer Society (ACS) guideline.

The ACS recently released an updated guideline recommending colorectal cancer screening starting at age 45 years for average-risk patients, in contrast to the USPSTF guideline, released June 2016, which recommends screening from age 50 through 75 years. The ACS acknowledged that the recommendation on screening those aged 45 to 49 years is graded as a qualified recommendation, as it relies on use of modeling without clinical trial-based evidence.

The AAFP agrees with the USPSTF recommendation for screening patients at ages 50 to 75 years, and graded its recommendation B. In addition, the AAFP offered a preferential recommendation for specific screening tests: fecal immunochemical tests, flexible sigmoidoscopy, and colonoscopy.

The ACS "assumed that colon cancer in younger adults is similar to cancer that occurs in older adults, and that screening would have the same benefits and no additional harms," Jennifer Frost, M.D., medical director for the AAFP's Health of the Public and Science Division, said in a statement. "Individual family physicians, in conversation with their patients, will decide whether earlier screening is appropriate. The AAFP will review empirical evidence once it is available."

AAFP Recommendation
ACS Policy Update

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »